Intravenous Immunoglobulins (IVIG) Market is poised for steady expansion due to rising incidences of immune disorders, increasing geriatric population, and growing demand for effective immunotherapy. Intravenous immunoglobulins are blood products used to treat various autoimmune, infectious, and idiopathic diseases by boosting immune responses. With advancements in plasma fractionation technologies and improved healthcare infrastructure, the IVIG market is projected to witness significant growth over the coming years.

The intravenous immunoglobulins market was valued at USD 17.00 billion in 2024 and is expected to grow from USD 18.40 billion in 2025 to USD 33.81 billion by 2032, reflecting a compound annual growth rate (CAGR) of 9.1% during the 2025–2032 period. North America led the market in 2024, accounting for a 57.09% share.

Top Companies in the Market

• Shire (Takeda Pharmaceutical Company Limited)
• CSL Behring
• Grifols, S.A.
• Kedrion S.p.A
• Octapharma
• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings, Inc.
• LFB SA
• Shanghai RAAS Blood Products Co., Ltd.

Market Drivers and Trends

Key drivers of the IVIG market include:

• Rising prevalence of immunodeficiency disorders such as primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and Kawasaki disease.
• Growing geriatric population globally, which is more susceptible to immune-related diseases.
• Increased awareness and diagnosis of rare and chronic autoimmune conditions.